Accord Healthcare
As of the edition of 20 October 2026, Accord Healthcare runs 17 drugs, 17 of them marketed; it is on route A at 0 targets and on route B at 3 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 3 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 17 |
| Total | 17 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Gemcitabine | none listed | 1 |
| Docetaxel anhydrous | none listed | 0 |
| Doxorubicin | none listed | 3 |
| Methotrexate | none listed | 2 |
| Pemetrexed | none listed | 7 |
| Bortezomib | none listed | 1 |
| Buprenorphine | Ends 2028 (exclusivity) | 9 |
| Leuprolide | Ended 2026 (exclusivity) | 1 |
| Carmustine | none listed | 1 |
| Naloxone | none listed | 10 |
| Serplulimab | none listed | 0 |
| Atropine | none listed | 12 |
| Cabazitaxel | Ended 2025 (patent) | 0 |
| Paricalcitol | none listed | 1 |
| Relugolix | Ends 2033 (patent) | 3 |
| Tigecycline | none listed | 0 |
| Argatroban | none listed | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 3 targets.
All 3 rows on route A or B
In the product3 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 3 targets where Accord Healthcare needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.